By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Rigel Pharmaceuticals, Inc. 

1180 Veterans Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-624-1100 Fax: 650-624-1101

Rigel's. Rigel's mission is to become a source of novel, small-molecule drugs to address large, unmet medical needs. We have initiated four development programs: asthma/allergy, hepatitis C, rheumatoid arthritis and oncology. Our first two product candidates, R112 for allergic rhinitis and R803 for hepatitis C, are in clinical testing. We expect to begin a clinical trial of R406 for the treatment of rheumatoid arthritis by the end of 2004, to be followed by initiation of clinical trials with additional product candidates for indications in oncology and asthma. Our approach to drug discovery is based on advanced, proprietary techniques that allow us to identify targets with a demonstrable role in a disease pathway and to screen efficiently for those targets that are likely to be amenable to drug modulation. We believe that this approach to drug discovery will enable us to commence clinical trials with one to two lead compounds each year. Our research efforts are focused in the areas of immunology/inflammation, virology and oncology.

Last Updated: 10-18-04

Key Statistics

Ownership: Public

Web Site: Rigel
Employees: 135
Symbol: RIGL


Drug Discovery

Company News
Rigel (RIGL) Announces Second Quarter 2016 Financial Results And Provides Portfolio Update 8/3/2016 9:34:19 AM
Rigel (RIGL) Announces Conference Call And Webcast To Report Second Quarter 2016 Financial Results 7/26/2016 7:59:29 AM
Rigel (RIGL) To Present At Jefferies 2016 Healthcare Conference 6/2/2016 8:53:02 AM
Rigel (RIGL) To Present At Upcoming American Association Of Immunologists (AAI) Annual Meeting 5/5/2016 7:57:48 AM
Rigel (RIGL) Announces First Quarter 2016 Financial Results 5/4/2016 7:02:24 AM
Rigel (RIGL) Announces Conference Call And Webcast To Report First Quarter 2016 Financial Results 4/26/2016 8:00:39 AM
Rigel (RIGL) Announces Presentations At Upcoming AACR Conference 4/12/2016 7:22:40 AM
Rigel (RIGL) Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP 4/1/2016 6:07:16 AM
Rigel (RIGL) Announces Fourth Quarter And Year End 2015 Financial Results 3/9/2016 7:31:41 AM
Rigel (RIGL) Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer 3/9/2016 6:13:30 AM